| abstract |
A retroviral protease inhibiting compound is diclosed. The compound is of the formula (see formula I) wherein R1 is hydrogen and R2 and R3 are independently selected from C6-aryl-C1-to-C6-alkyl, C9-to-C10-aryl-C1-to-C6-alkyl, C3-to-C7-cycloalkyl-C1-to-C6-alkyl and (heterocyclic)-C1-to-C6-alkyl; and A and B are independently selected from R6-C(O)-(NH)-(CH(R5))-C(O)- and R6-C(O)- wherein at each occurrence R6 is independently selected from R7-N(C1-to-C6-loweralkyl)-, R7-O- and R7-S- wherein R7 is heterocyclic or (heterocyclic)-C1-to-C6-alkyl and at each occurrence R5 is independently selected from C1-to-C6-loweralkyl; or a pharmaceutically acceptable salt, thereof. Also disclosed are a composition use and kit for inhibiting a retroviral protease and for treating an HIV infection. Also disclosed are processes and intermediates useful for the preparation of the retroviral protease inhibitors. |